New hope for hard-to-treat colorectal cancer: targeted drug aims to extend life with fewer side effects
NCT ID NCT07213570
First seen Nov 01, 2025 · Last updated May 14, 2026 · Updated 26 times
Summary
This study tests whether the drug regorafenib can help people with a specific type of advanced colorectal cancer (RAS-mutant) who have already tried one treatment. The goal is to see if a less intensive approach can keep the cancer from growing for at least 6 months while maintaining quality of life. About 60 adults with stable disease or only one tumor site will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER METASTATIC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Istituto Nazionale Tumori | "Fondazione Pascale"
RECRUITINGNaples, Italy, Italy
Conditions
Explore the condition pages connected to this study.